1White IN. Tamoxifen, is it safe Comparison of activation and detoxication mechanisms in rodents and in humans[ J]. Carr Drug Metab ,2003,4:223-239.
2Dehal SS, Kupfer D. CYP2D6eatalyzes tamoxifen 4-hydroxylation in human liver [ J ]. Cancer Res ,1997,57:3402-3406.
3Ron HN, van S. CYP450 pharmaeogenetics for personalizing cancer therapy [J]. Drug Resist Updat ,2008 ,11( 3 ) :77-98.
4Hu YF,He J,Chen GL,et al. CYP3A5 * 3 and CYP3A4 * 18 single nucleotide polymorphisms in a Chinese population [ J ]. Clini Chim Acta, 2005,353 ( 1-2 ) : 187-192.
5Huang W, Lin YS, McConn D J, et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism [ J ]. Drug Metab Dispos, 2004,32 : 1434- 1445.
6April N, Tttckera KA, Tkaczukb, et al. Polymozphisms in cytoehrome P4303A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients[J]. Cancer Letters ,2005,1:61-72.
7Pia W,Sauli E,John C,et al. Genetic variants of CYP3AS,CYP2D6,SULTlAI, UGT2B15 and tamoxifen respanse in postmenopausal patients with breast cancer [J]. Breast Cancer Res,2007,9( 1 ) :R7.
8Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [ J ].Nat Genet,2001,27 ( 4 ) : 383 -391.
9Cai WM, Chen B, Liu YX, et al. Dextromethorphan metabolic pbenotyping in a native Chinese population [ J ]. Acta Pharmacol Sin, 1997,18 ( 5 ) :441-444.
10Xu Y, Sun Y, Yao L, et al. Association between CYP2D6 * 10 genotype and survival of breast cancer patients receiving tamoxifen treatment[ J ]. Ann Oncol, 2008,!9(8) : 1423-1429.
